Form 4: Teladoc Executive Sells Shares Under 10b5-1 Plan

Fernando M. Rodrigues, President of BetterHelp at Teladoc Health, Inc., reported a sale of 9,572 shares of common stock executed on June 3, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Fernando M. Rodrigues, President of BetterHelp, sold 9,572 shares of Teladoc Health, Inc. common stock.
• The transaction occurred on June 3, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on November 3, 2025.
• The shares were sold at a price of $7.40 per share.
• Following the transaction, Rodrigues directly beneficially owns 0 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the executive's sale of shares, despite the transaction being executed under a pre-defined 10b5-1 plan.

Negatives

• Executive sale of a significant number of shares, although conducted under a pre-established plan, may be perceived negatively by the market.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, even those executed under Rule 10b5-1 plans, are closely monitored by investors as they can sometimes signal a lack of confidence in future stock performance, though the existence of the plan itself is designed to mitigate concerns about opportunistic trading.

Stakeholder Impact

• Shareholders may view the executive's sale of shares with caution, potentially impacting short-term investor sentiment.
• Employees may interpret the sale as a signal from management, though the 10b5-1 plan mitigates concerns about insider knowledge.

Key Dates

Recommendation

The filing reports an insider sale under a Rule 10b5-1 plan, which is a standard practice for executives to diversify holdings or manage personal finances without implying non-public information. While insider selling can be a negative signal, the pre-planned nature of this transaction suggests it's not necessarily a reflection of a negative outlook on the company's future prospects. Therefore, a 'hold' recommendation is appropriate, pending further company performance and strategic updates.

Keywords

Form 4, Insider Trading, Rule 10b5-1, Teladoc Health, TDOC, Stock Sale, Beneficial Ownership, Executive Compensation